Current Therapeutic Strategies in BRAF|Mutant Metastatic ...

Targeting BRAF V600E in metastatic colorectal cancer - ecancer

Dr Guerrero explains the key findings of this review showed immunotherapy, the combination of BRAF and EGFR inhibitors and the combination of ...

Targeting BRAF V600E in metastatic colorectal cancer - ecancer

Recently, randomised clinical trials have studied the combination of different chemotherapy regimens with angiogenic inhibitors in mCRC BRAFm.

Clinical management of metastatic colorectal cancer in the era of ...

In fact, treatment with anti-EGFR drugs eliminates RAS/BRAF WT-sensitive clones, whereas acquired RAS-mutant–resistant clones become the ...

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF ...

While compelling preclinical data have highlighted the effectiveness of combination therapy with vemurafenib and small-molecule EGFR inhibitors, gefitinib or ...

BRAF mutations as a therapeutic target in metastatic colorectal ...

BRAF V600 mutations have long been of interest in the field of targeted therapeutics. Recently, combined approaches with EGFR blockade and BRAF inhibitors, with ...

Survival comparison of first-line treatment regimens in patients with ...

At present, according to the 2021 Chinese Society of Clinical Oncology (CSCO) guidelines, the first-line of treatment for patients with BRAF- ...

Development of small-molecule therapeutics and strategies for targetin

A combination of EGFR suppression and vemurafenib, a BRAF inhibitor, leads to synergistic cytotoxicity. A combined therapy of irinotecan and ...

A Treatment Evolution Is Underway in BRAF V600E–Mutated mCRC

Biomarker expression is driving treatment decision-making. “CRC with a BRAF mutation is a more aggressive form of cancer that doesn't respond to ...

Encorafenib plus cetuximab for the treatment of BRAF-V600E ...

improve the current results for this ... BRAF, MEK and EGFR inhibition as treatment strategies in. BRAF V600E metastatic colorectal cancer.

Addressing Resistance to Targeted Therapies in Metastatic ...

This finding has been subsequently bolstered by multiple retrospective reviews; however, given the relative rarity of BRAF V600E mutations in ...

Anti-EGFR Maintenance Therapy in Metastatic Colorectal Cancer

According to current guidelines, doublet chemotherapy plus an anti–epidermal growth factor receptor (EGFR) agent is the recommended upfront ...

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of ...

Current Treatment Landscape in BRAF-Mutated mCRC ... MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer.

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated ...

Genetically-targeted therapies are both promising and costly advances in the field of oncology. Several treatments for metastatic melanoma with a mutation in ...

Case 1: BRAF-Mutated Metastatic Colorectal Cancer - YouTube

Shubham Pant, MD, reviews the diagnostic workup of a 73-year-old man with BRAF-mutated metastatic colon cancer and comments on recent data.

Breast Cancer - Guidelines Detail - NCCN

NCCN Tumor Boards: Treatment Selection Strategies and Barriers to Clinical Care in Metastatic Breast Cancer · Recorded Presentation from the NCCN Pharmacy ...

Pipeline - AstraZeneca

Jump to section: · Oncology · Cardiovascular, Renal and Metabolism · Respiratory & Immunology · Rare Disease · Vaccine & Immune therapies · Other ...

BLA Filed for Dato-DXd for EGFR-Mutant Lung Cancer

... treatment of patients with advanced or metastatic nonsquamous NSCLC. ... therapeutic strategy among this patient population. “Glycan editing ...

How to Approach the Patient With BRAF Mutant Tumor - YouTube

Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma ... Case 2: BRAF-Mutated Metastatic Melanoma. Targeted ...

Colorectal cancer - Wikipedia

... current treatment strategies. Diagnosis. edit. Colon cancer with extensive metastases to the liver. Colorectal cancer diagnosis is performed by sampling ...

Full Program - San Antonio Breast Cancer Symposium

Case 4: Selecting treatment for patient with tumor ESR1 mutation ... Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer ...